Latest news
Silexion Therapeutics (SLXN US): Synthetic Expert Call Transcript (10 Aug 2026) - SmartkarmaSmartkarma · Mon, 10 Aug 2026 07:21:48 GMTSilexion Therapeutics publishes corporate deck spotlighting SIL204 siRNA program targeting KRAS-driven cancers - BitgetBitget · Sun, 09 Aug 2026 13:24:56 GMTIPO Databook: Silexion Therapeutics (SLXN US) - Aug 2026 - SmartkarmaSmartkarma · Sat, 08 Aug 2026 07:00:00 GMTSilexion Therapeutics (NASDAQ: SLXN) files S-1 for best-efforts unit sale - Stock TitanStock Titan · Fri, 07 Aug 2026 22:52:53 GMTCancer treatment makes tumor vulnerable to immune system attack, research finds - The Jerusalem PostThe Jerusalem Post · Wed, 05 Aug 2026 11:47:00 GMTSilexion to present preclinical data on SIL-204 at GI cancer event - Investing.comInvesting.com · Tue, 04 Aug 2026 15:03:49 GMTSilexion Therapeutics Reports New Positive Preclinical - GlobeNewswireGlobeNewswire · Tue, 04 Aug 2026 13:15:00 GMTSilexion's SIL204 Alters Three Immune Pathways in Cancer Cells - Stock TitanStock Titan · Tue, 04 Aug 2026 13:15:00 GMT